KMT2A genomic fusion is a more reliable MRD marker than IG/TR to assess treatment response. (A) Flowchart of the study design. (B) Comparison of the MRD levels between IG/TR and KMT2A genomic fusion (gKMT2A) measured at MRD1 and MRD2. (C) Illustrative cases showing discordant MRD results between gKMT2A and IG/TR markers CIR and OS in patients at the end of induction (MRD1) according to IG/TR and gKMT2A markers (D-E) and according to gKMT2A marker only (F-G), including 5 additional patients without IG/TR MRD because of the lack of clonal IG/TR rearrangement. PNQ, positive not quantifiable; Undet, undetectable.